Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27485110 | 0.82 | ALDH1A1 (0.48) | ALDH1A1TSHRPAOXSIGMAR1KDM4E | |
| SCHEMBL12678284 | 0.80 | PAOX (0.55) | ALDH1A1TSHRPAOXSIGMAR1KDM4E | |
| SCHEMBL8038150 | 0.80 | HSD17B10 (0.52) | ALDH1A1TSHRPAOXSIGMAR1KDM4E | |
| SCHEMBL27018154 | 0.80 | HSD17B10 (0.52) | ALDH1A1TSHRPAOXSIGMAR1KDM4E | |
| SCHEMBL3626700 | 0.80 | HSD17B10 (0.52) | ALDH1A1TSHRPAOXSIGMAR1KDM4E | |
| SCHEMBL15140 | 0.80 | HSD17B10 (0.52) | ALDH1A1TSHRPAOXSIGMAR1KDM4E | |
| SCHEMBL9391670 | 0.80 | HSD17B10 (0.52) | ALDH1A1TSHRPAOXSIGMAR1KDM4E | |
| SCHEMBL762874 | 0.80 | PAOX (0.55) | ALDH1A1TSHRPAOXSIGMAR1KDM4E | |
| SCHEMBL12238110 | 0.80 | HSD17B10 (0.52) | ALDH1A1TSHRPAOXSIGMAR1KDM4E | |
| SCHEMBL17022243 | 0.80 | HSD17B10 (0.52) | ALDH1A1TSHRPAOXSIGMAR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0765160-B1 | DEXANABINOL DERIVATIVES AND THEIR USE AS NEUROPROTECTIVE PHARMACEUTICAL COMPOSITIONS | UNIV RAMOT (IL) | 2003-04-16 | — | — | EP | claimed |
| US-6096740-A | BLOCK N-METHYL-ASPARTATE | RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH AND INDUSTRIAL DEVELOPMENT LTD. (IL) | 2000-08-01 | — | — | US | claimed |
| EP-0765160-A4 | — | — | 1997-04-09 | — | — | EP | claimed |
| EP-0765160-A1 | DEXANABINOL DERIVATIVES AND THEIR USE AS NEUROPROTECTIVE PHARMACEUTICAL COMPOSITIONS | RAMOT UNIVERSITY, AUTHORITY FOR APPLIED RESEARCH & INDUSTRIAL DEVELOPMENT LTD. (IL) | 1997-04-02 | — | — | EP | claimed |
| WO-1995020958-A1 | DEXANABINOL DERIVATIVES AND THEIR USE AS NEUROPROTECTIVE PHARMACEUTICAL COMPOSITIONS | RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH AND INDUSTRIAL DEVELOPMENT LTD. (IL) | 1995-08-10 | — | — | WO | claimed |
| US-20050130941-A1 | Methods of treating alzheimer's disease | PHARMACIA & UPJOHN COMPANY LLC | 2005-06-16 | — | — | US | disclosed |
| EP-1392315-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-03-03 | — | — | EP | disclosed |
| EP-0765160-B1 | DEXANABINOL DERIVATIVES AND THEIR USE AS NEUROPROTECTIVE PHARMACEUTICAL COMPOSITIONS | UNIV RAMOT (IL) | 2003-04-16 | — | — | EP | disclosed |
| WO-2002100410-A1 | METHODS OF TREATING ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| US-6096740-A | BLOCK N-METHYL-ASPARTATE | RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH AND INDUSTRIAL DEVELOPMENT LTD. (IL) | 2000-08-01 | — | — | US | disclosed |
| US-5753652-A | Antiretroviral hydrazine derivatives | NOVARTIS CORPORATION (US) | 1998-05-19 | — | — | US | disclosed |
| EP-0765160-A4 | — | — | 1997-04-09 | — | — | EP | disclosed |
| WO-1995020958-A1 | DEXANABINOL DERIVATIVES AND THEIR USE AS NEUROPROTECTIVE PHARMACEUTICAL COMPOSITIONS | RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH AND INDUSTRIAL DEVELOPMENT LTD. (IL) | 1995-08-10 | — | — | WO | disclosed |
| EP-0604368-A1 | Anti retroviral hydrazine derivatives | CIBA-GEIGY AG (CH) | 1994-06-29 | — | — | EP | disclosed |
| US-5302730-A | Acylation with acetic acid at positions one and seven; eliminating acyl group at position seven by solvolysis | NIPPON KAYAKU KK (JP) | 1994-04-12 | — | — | US | disclosed |
| EP-0297496-B1 | Novel process for the preparation of 6,7-Diacyl-7-deacetylforskolin derivatives | NIPPON KAYAKU KK (JP) | 1994-01-19 | — | — | EP | disclosed |
| US-5245052-A | PROCESS FOR PRODUCING 6-ACYL-7-DEACETYLFORSKOLIN DERIVATIVES | NIPPON KAYAKU CO. LTD. (JP) | 1993-09-14 | — | — | US | disclosed |
| EP-0469428-A1 | Novel process for producing 6-acyl-7-deacetylforskolin derivatives | HOECHST JAPAN LIMITED (JP) | 1992-02-05 | — | — | EP | disclosed |
| US-4914206-A | ANTIBIOTICS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1990-04-03 | — | — | US | disclosed |
| EP-0297496-A2 | Novel process for the preparation of 6,7-Diacyl-7-deacetylforskolin derivatives | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1989-01-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130941-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, BACE2 | ALDH1A1 889/4885TSHR 2585/4885PAOX 2695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.